Eledon’s Tegoprubart Shows Sustained Kidney Function Advantage in Phase 2 Extension Study
Event summary
- Tegoprubart-treated patients maintained a 13 mL/min/1.73 m² advantage in kidney function over tacrolimus at 24 months.
- No rejections occurred in the tegoprubart arm beyond six months post-transplant, compared with seven in the tacrolimus arm.
- FDA granted Fast Track designation to tegoprubart for kidney transplant rejection prevention.
- Phase 3 LEGACY study expected to initiate in Q4 2026.
The big picture
Eledon’s updated Phase 2 data for tegoprubart underscores its potential to challenge tacrolimus as the standard of care in kidney transplantation. The FDA’s Fast Track designation accelerates the path to market, but the success of the Phase 3 LEGACY study will be critical in determining tegoprubart’s long-term viability. The biotech sector is increasingly focused on innovative immunosuppression therapies, and Eledon’s progress could influence broader trends in transplant medicine.
What we're watching
- Clinical Validation
- Whether the sustained eGFR advantage of tegoprubart will translate into long-term clinical benefits and regulatory approval.
- Regulatory Pathway
- The pace at which the FDA will review tegoprubart under the Fast Track designation and the potential for Accelerated Approval.
- Market Differentiation
- How Eledon positions tegoprubart against existing immunosuppression therapies in the kidney transplant market.
Related topics